Cas No.: | 265121-04-8 |
名称: | D-Glucitol, 1-deoxy-1-(methylamino)-, [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]phosphonate (2:1) |
别名: | |
SMILES: | O=C1N=C(CN2[C@@H](C3=CC=C(F)C=C3)[C@@H](O[C@H](C)C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)OCC2)NN1P(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC |
分子式: | C23H22F7N4O6P.2C7H17NO5 |
分子量: | 1004.83 |
纯度: | |
保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | |
In Vivo: | |
In Vitro: | |
References: | Fosaprepitant is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008, and by the European Me |
Kinase Assay: | |
Cell Assay: | |
Animal Administration: | |
References: |